Science Advisory Board to the National Center for Toxicological Research; Notice of Meeting, 45057 [E6-12863]
Download as PDF
Federal Register / Vol. 71, No. 152 / Tuesday, August 8, 2006 / Notices
and falsifying patient data in research
supported by National Institute on
Aging (NIA), National Institutes of
Health (NIH), grant R01 AG18461.
Specifically, Ms. Okoro intentionally
and knowingly fabricated and falsified
data for six visit dates on one patient
data form and falsified and fabricated
patient condition information on two
additional study subjects by failing to
note that each patient had experienced
a fall as documented in their medical
charts.
ORI has implemented the following
administrative actions for a period of
three (3) years, beginning July 17, 2006:
(1) Ms. Okoro is prohibited from
serving in any advisory capacity to PHS,
including but not limited to service on
any PHS advisory committee, board,
and/or peer review committee, or as a
consultant; and
(2) Any institution that submits an
application for PHS support for a
research project on which Ms. Okoro’s
participation is proposed or which uses
her services in any capacity on PHS
supported research must concurrently
submit a plan for supervision of her
duties. The supervisory plan must be
designed to ensure the scientific
integrity of Ms. Okoro’s research
contribution and must be submitted to
ORI by the institution.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
Oversight, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8800.
Chris B. Pascal, J.D.,
Director, Office of Research Integrity.
[FR Doc. E6–12857 Filed 8–7–06; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Science Advisory Board to the
National Center for Toxicological
Research; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
jlentini on PROD1PC65 with NOTICES
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). At least one portion of the
meeting will be closed to the public.
Name of Committee: Science
Advisory Board (SAB) to the National
Center for Toxicological Research
(NCTR).
General Function of the Committee:
The Board advises the Director, NCTR,
VerDate Aug<31>2005
20:06 Aug 07, 2006
Jkt 208001
in establishing, implementing, and
evaluating the research programs that
assist the Commissioner of Food and
Drugs in fulfilling his regulatory
responsibilities. The Board provides an
extra-agency review in ensuring that the
research programs at NCTR are
scientifically sound and pertinent.
Date and Time: The meeting will be
held on August 29, 2006 from 8:30 a.m.
to 4:30 p.m. and on August 30, 2006,
from 8 a.m. to 12 noon.
Location: August 29, 2006: NCTR SAB
Conference Room B–12, 3900 NCTR Dr.,
Jefferson, AR 72079. August 30, 2006:
University of Arkansas for Medical
Sciences, Stephens Spine Center,
Hamlin Board Room, 501 Jack Stephens
Dr., Little Rock, AR 72205.
Contact Person: Leonard Schechtman,
Executive Secretary, National Center for
Toxicological Research, Food and Drug
Administration, 5600 Fishers Lane, rm.
16–85, Rockville, MD 20857, 301–827–
6696, or FDA Advisory Committee
Information Line, 1–800–741–8138
(301–443–0572 in the Washington, DC
area), code 3014512559. Please call the
Information Line for up-to-date
information on this meeting.
Agenda: On August 29, 2006, the SAB
will hear presentations from the NCTR
Divisions that will update them on
ongoing research activities. The SAB
will be presented with a response to the
evaluation of the Division of
Neurotoxicology. The evaluation was
the product of a site visit team that
conducted an on-site review of the
Division in January 2004. The response
will address the issues raised and
recommendations made by the site visit
team. On August 30, 2006, the NCTR
Director will provide a Center-wide
update on scientific endeavors and will
discuss the NCTR realignment and
strategic focus.
Procedure: On August 29, 2006, from
8:30 a.m. to 4:30 p.m., and August 30,
2006, from 8 a.m. to 10:30 a.m., the
meeting is open to the public. Interested
persons may present data, information,
or views, orally or in writing, on issues
pending before the committee. Written
submissions may be made to the contact
person on or before August 14, 2006.
Oral presentations from the public will
be scheduled on August 29, 2006,
between approximately 12:30 p.m. to
1:30 p.m. Time allotted for each
presentation may be limited. Those
desiring to make formal oral
presentations should likewise notify the
contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
45057
requested to make their presentation on
or before August 14, 2006.
Closed Committee Deliberations: On
August 29, 2006, from approximately 11
a.m. to 12:30 p.m., the meeting will be
closed to permit discussion where
disclosure would constitute a clearly
unwarranted invasion of personal
privacy (5 U.S.C. 552b(c)(6)). This
portion of the meeting will be closed to
permit discussion of information
concerning individuals associated with
the research programs at NCTR.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact the office of
the Executive Secretary at least 7 days
in advance of the meeting.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: August 2, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6–12863 Filed 8–7–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 1992S–0251] (formerly 92S–
0251)
Food and Drug Administration
Electronic Submissions Gateway
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of the FDA Electronic
Submissions Gateway (ESG) for the
receipt and processing of electronic
submissions provided so that the Center
for Biologics Evaluation and Research
(CBER), the Center for Drug Evaluation
and Research (CDER), and the Center for
Devices and Radiological Health (CDRH)
can receive regulatory submissions
electronically. The FDA ESG enables
applicants to send applications and
other submissions for review using the
Internet, provides a single point of entry
for these submissions, and fulfills goals
identified in the Prescription Drug User
Fee Act (PDUFA III).
E:\FR\FM\08AUN1.SGM
08AUN1
Agencies
[Federal Register Volume 71, Number 152 (Tuesday, August 8, 2006)]
[Notices]
[Page 45057]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-12863]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Science Advisory Board to the National Center for Toxicological
Research; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). At least one
portion of the meeting will be closed to the public.
Name of Committee: Science Advisory Board (SAB) to the National
Center for Toxicological Research (NCTR).
General Function of the Committee: The Board advises the Director,
NCTR, in establishing, implementing, and evaluating the research
programs that assist the Commissioner of Food and Drugs in fulfilling
his regulatory responsibilities. The Board provides an extra-agency
review in ensuring that the research programs at NCTR are
scientifically sound and pertinent.
Date and Time: The meeting will be held on August 29, 2006 from
8:30 a.m. to 4:30 p.m. and on August 30, 2006, from 8 a.m. to 12 noon.
Location: August 29, 2006: NCTR SAB Conference Room B-12, 3900 NCTR
Dr., Jefferson, AR 72079. August 30, 2006: University of Arkansas for
Medical Sciences, Stephens Spine Center, Hamlin Board Room, 501 Jack
Stephens Dr., Little Rock, AR 72205.
Contact Person: Leonard Schechtman, Executive Secretary, National
Center for Toxicological Research, Food and Drug Administration, 5600
Fishers Lane, rm. 16-85, Rockville, MD 20857, 301-827-6696, or FDA
Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in
the Washington, DC area), code 3014512559. Please call the Information
Line for up-to-date information on this meeting.
Agenda: On August 29, 2006, the SAB will hear presentations from
the NCTR Divisions that will update them on ongoing research
activities. The SAB will be presented with a response to the evaluation
of the Division of Neurotoxicology. The evaluation was the product of a
site visit team that conducted an on-site review of the Division in
January 2004. The response will address the issues raised and
recommendations made by the site visit team. On August 30, 2006, the
NCTR Director will provide a Center-wide update on scientific endeavors
and will discuss the NCTR realignment and strategic focus.
Procedure: On August 29, 2006, from 8:30 a.m. to 4:30 p.m., and
August 30, 2006, from 8 a.m. to 10:30 a.m., the meeting is open to the
public. Interested persons may present data, information, or views,
orally or in writing, on issues pending before the committee. Written
submissions may be made to the contact person on or before August 14,
2006. Oral presentations from the public will be scheduled on August
29, 2006, between approximately 12:30 p.m. to 1:30 p.m. Time allotted
for each presentation may be limited. Those desiring to make formal
oral presentations should likewise notify the contact person and submit
a brief statement of the general nature of the evidence or arguments
they wish to present, the names and addresses of proposed participants,
and an indication of the approximate time requested to make their
presentation on or before August 14, 2006.
Closed Committee Deliberations: On August 29, 2006, from
approximately 11 a.m. to 12:30 p.m., the meeting will be closed to
permit discussion where disclosure would constitute a clearly
unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). This
portion of the meeting will be closed to permit discussion of
information concerning individuals associated with the research
programs at NCTR.
Persons attending FDA's advisory committee meetings are advised
that the agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact the office of the
Executive Secretary at least 7 days in advance of the meeting.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: August 2, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6-12863 Filed 8-7-06; 8:45 am]
BILLING CODE 4160-01-S